Overview

This trial is active, not recruiting.

Condition lymphoma
Treatments gene expression analysis, microarray analysis, polymorphism analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, immunologic technique
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date April 2007
Trial size 175 participants
Trial identifier NCT00898963, CDR0000544400, ECOG-E1496T1

Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.

PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Measure
Correlation of gene expression profiles with progression-free survival (PFS)
time frame:
Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry
time frame:
Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers
time frame:
Correlation of relevant biomarkers with clinical features, response, and PFS
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diagnosis of follicular lymphoma - Stage III or IV disease - Received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Additional Information

Official title Identification of Biomarkers in Follicular Lymphoma
Description OBJECTIVES: - Correlate gene expression profiles with progression-free survival (PFS) of patients with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496. - Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in these patients. - Assess the significance of the microenvironment by constructing tissue microarrays of follicular lymphoma and immunostaining with relevant biomarkers. - Correlate relevant biomarkers with clinical features, response, and PFS. OUTLINE: This is a multicenter study. Tissue samples are analyzed by gene expression profiling, microarrays to predict gene expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis for biological markers. PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).